touchTALKS Multiple sclerosis in older patients: A patient population with unique needs
Join Prof. Gavin Giovannoni as he discusses important considerations concerning the management of older patients with MS.
What are immuno- and neuro-senescence and how do they impact older patients with MS?
Prof. Giovannoni describes how the process of normal ageing or senescence is hardwired and has the potential to impact how MS is managed.
view bio and disclosures 1/3 Next ChapterWhat is the role for DMTs in older patients with MS?
Prof. Giovannoni summarizes the interactions between ageing and MS, and how the principles of treating MS with DMTs apply regardless of age, considering important factors such as safety and comorbidities.
view bio and disclosures 2/3 Next ChapterHow will practice change in the near future for older patients with MS?
Recapping the implications that natural immunosenescence with ageing has for the management of MS, Prof. Giovannoni highlights the urgent need for proactivity in terms of stopping and/or derisking immunosuppressive DMTs and the importance of combining holistic strategies.
view bio and disclosures 3/3 Take CE/CME TestLearning Objectives & Overview
Overview
In this activity, Prof. Gavin Giovannoni shares his clinical expertise relating to the optimization of disease-modifying therapies for MS with a focus on the impact that immuno- and neuro-senescence place on patients as they age.
This activity has been jointly provided by Oakstone and touchIME for touchNEUROLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
Target Audience
This activity has been designed to meet the educational needs of neurologists, MS specialists, neurology nurses, primary care physicians and other relevant healthcare professionals involved in the multidisciplinary management of patients with MS.
Disclosures
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest have been mitigated. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relationships with ineligible entities.
Faculty
Prof. Gavin Giovannoni discloses: Consultation/advisory role fees from AbbVie, Almirall, Atara Bio, Bayer-Schering Healthcare, Biogen, Bristol-Myers Squibb, BMS-Celgene, Canbex, Eisai, Elan, Five Prime Therapeutics, Genentech, GlaxoSmithKline, GW Pharma, Ironwood, Janssen, Janssen-Actelion, Japan Tobacco, Merck, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Genzyme, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals.
Content Reviewer
Walter Murray Yarbrough, MD, FACP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Christina Mackins-Crabtree has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 29 April 2021. Date credits expire: 29 April 2022.
Learning Objectives
After watching this activity, participants should be better able to:
- Summarize the impact of immuno- and neuro-senescence on disease management for older patients with MS
- Explain how to apply the data supporting the use of DMTs in daily practice
- Discuss the data published in 2020 that will change the way older patients with MS are treated
About Prof. Gavin Giovannoni
Prof. Gavin Giovannoni
Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Gavin Giovannoni is the Professor of Neurology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London and the Department of Neurology, Barts Health NHS Trust. His clinical interests are MS and other inflammatory disorders of the central nervous system. He is particularly interested in clinical issues related to optimizing MS disease-modifying therapies. His current research is focused on Epstein–Barr virus as a possible cause of MS, defining the ‘MS endophenotype’, MS-related neurodegeneration, biomarker discovery and validation, and MS clinical outcomes. His team focuses on translational research and therefore has an active clinical trial programme.
Prof. Gavin Giovannoni discloses: Consultation/advisory role fees from AbbVie, Almirall, Atara Bio, Bayer-Schering Healthcare, Biogen, Bristol-Myers Squibb, BMS-Celgene, Canbex, Eisai, Elan, Five Prime Therapeutics, Genentech, GlaxoSmithKline, GW Pharma, Ironwood, Janssen, Janssen-Actelion, Japan Tobacco, Merck, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Genzyme, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals.
Register to touchNEUROLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
